Holen Sie sich die Stockscreener-App
3.63
3.12%
0.11
Handel nachbörslich:
3.66
0.03
+0.83%
Schlusskurs vom Vortag:
$3.52
Offen:
$3.59
24-Stunden-Volumen:
2.26M
Relative Volume:
0.71
Marktkapitalisierung:
$655.40M
Einnahmen:
$4.63M
Nettoeinkommen (Verlust:
$-201.14M
KGV:
-2.6417
EPS:
-1.3741
Netto-Cashflow:
$-167.10M
1W Leistung:
+2.83%
1M Leistung:
-12.11%
6M Leistung:
-30.46%
1J Leistung:
+86.15%
1-Tages-Spanne:
$3.585
$3.75
1-Wochen-Bereich:
$3.43
$3.77
52-Wochen-Spanne:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.63 | 635.54M | 4.63M | -201.14M | -167.10M | -1.3741 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
Support Test: Does Prime Medicine Inc have declining or rising EPSWeekly Risk Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Prime Medicine slips after Q4 updates - MSN
Aug PostEarnings: Is Prime Medicine Inc a strong growth stock2026 Trade Ideas & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Prime Medicine (PRME) focuses on liver franchise with $191.4M cash runway - MSN
Prime Medicine, Inc. (PRME) reports Q4 loss, misses revenue estimates - MSN
Hedge Fund Bets: Whats the fair value of Prime Medicine Inc stock2026 Institutional & Risk Managed Investment Entry Signals - baoquankhu1.vn
Farallon Capital Management LLC Buys 4,000,000 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Casdin Capital LLC Acquires 1,600,000 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Aug Weekly: Is Prime Medicine Inc backed by strong institutional buyingMarket Sentiment Review & Reliable Entry Point Alerts - baoquankhu1.vn
Oppenheimer Initiates Coverage on PRME with "Outperform" Rating - GuruFocus
Prime Medicine (NASDAQ:PRME) Shares Gap UpHere's Why - MarketBeat
Prime Medicine (NYSE:PRME) Shares Gap UpShould You Buy? - MarketBeat
Prime Medicine (NYSE:PRME) Earns Outperform Rating from Analysts at Oppenheimer - MarketBeat
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - MSN
Prime Medicine (NASDAQ:PRME) Trading Down 6.3%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Shares Down 6.9%Here's What Happened - MarketBeat
PRME Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway - Finviz
Will Prime Medicine Inc. stock outperform value stocksPrice Action & Technical Confirmation Alerts - Naître et grandir
Will Prime Medicine Inc. stock benefit from upcoming earnings reportsJuly 2025 Update & Growth Focused Entry Reports - Naître et grandir
10 Best New Penny Stocks to Buy - Insider Monkey
LifeSci Capital initiates Prime Medicine (PRME), highlights one-and-done potential in liver and lung diseases - MSN
Guidance Update: Will Prime Medicine Inc stock hit new highs in YEARPortfolio Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
HC Wainwright Predicts Stronger Earnings for Prime Medicine - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine, Inc. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
Lifesci Capital Predicts Prime Medicine FY2025 Earnings - MarketBeat
Prime Medicine, Inc. $PRME Shares Acquired by ARK Investment Management LLC - MarketBeat
Prime Medicine, Inc. $PRME Stock Position Increased by Amova Asset Management Americas Inc. - MarketBeat
[EFFECT] Prime Medicine, Inc. SEC Filing - Stock Titan
Citizens reiterates Prime Medicine stock rating on PM359 pathway - Investing.com Australia
Citizens reiterates Prime Medicine stock rating on PM359 pathway By Investing.com - Investing.com Canada
Prime Medicine (NASDAQ:PRME) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat
Prime to test FDA flexibility with 2-patient gene editing submission - BioPharma Dive
Prime Medicine (PRME) Quarterly Loss Near US$50 Million Reinforces Bearish Community Narratives - simplywall.st
Prime Medicine unveils full year 2025 financial results and business update as progress advances - Traders Union
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates - Bitget
Prime Medicine Reports 2025 Results, Advances Gene Editing Pipeline - TipRanks
Prime Medicine 2025 Net Loss Narrows as Revenue Rises -- Shares Fall Pre-Bell - marketscreener.com
Earnings Flash (PRME) Prime Medicine Posts 2025 Total Revenue $4.6M, vs. FactSet Est of $5.7M - marketscreener.com
Earnings Flash (PRME) Prime Medicine Posts 2025 Net Loss $1.35 a Share, vs. FactSet Est of $1.30 Loss - marketscreener.com
Prime Medicine : March 2026 Corporate Presentation - marketscreener.com
Prime Medicine 2025 net loss widens, hurt by higher R&D expenses - TradingView
Prime Medicine (Nasdaq: PRME) details 2025 results, cash runway and gene-editing milestones - Stock Titan
PRME Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Prime Medicine, Inc. (PRME) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Prime Medicine, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Investment Report: What is the target price for Prime Medicine Inc stockJuly 2025 Fed Impact & Low Risk High Reward Trade Ideas - baoquankhu1.vn
HighTower Advisors LLC Buys 312,401 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Stock Traders Buy Large Volume of Call Options on Prime Medicine (NYSE:PRME) - MarketBeat
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):